Journal of The Korean Society of Inherited Metabolic disease (대한유전성대사질환학회지)

The Korea Society of Inherited Metabolic Disease (대한유전성대사질환학회)
권호 표지

Long-term Clinical Course of a Korean Girl with β-ureidopropionase Deficiency

β-ureidopropionase 결핍증의 장기간의 임상경과 1례

  • Song, Woo Sun (Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Park, Youngjin (Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Lee, Jun Hwa (Department of Pediatrics, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine)
  • 송우선 (성균관대학교 삼성창원병원 소아과학교실) ;
  • 박영진 (성균관대학교 삼성창원병원 소아과학교실) ;
  • 이준화 (성균관대학교 삼성창원병원 소아과학교실)
  • Published : 2017.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

${\beta}$-ureidopropionase deficiency (${\beta}$-UPD; OMIM # 613161) is a rare autosomal recessive inborn error of pyrimidine metabolism caused by mutations in the UPB1 gene and approximately 30 cases have been reported in the world. The clinical features of patients with ${\beta}$-UPD have been reported to vary from asymptomatic to severe developmental delays. However, the long-term clinical courses of patients with ${\beta}$-UPD have not yet been reported. A Korean girl was diagnosed with ${\beta}$-UPD at the age of 8 years and 10 months by targeted next-generation sequencing which was subsequently confirmed by Sanger sequencing. She had many clinical features such as poor oral feeding, failure to thrive, global developmental delay, microcephaly, frequent infection, and intractable epilepsy. She died suddenly of an unknown cause at the age of 11 years and 5 months. Here we report the long-term (i.e. lifelong) clinical aspects of a Korean patient with ${\beta}$-UPD.

${\beta}$-ureidopropionase 결핍증(${\beta}$-UPD)은 UPB1 유전자 변이에 의한 피리미딘 대사 이상에 의해 생기는 매우 드문 상염색체 열성 유전 질환으로 현재까지 전 세계에서 30여명 정도만 보고되었다. ${\beta}$-UPD는 무증상인 경우부터 심한 발달 지연, 소두증, 발작, 인지 저하의 증상을 보이는 경우까지 다양하다. 국내에서 진단된 유일한 ${\beta}$-UPD 여자 환자는 8세 10개월에 targeted next-generation sequencing 검사로 UPB1 유전자 변이를 확인 한 후, Sanger sequencing을 통해 확진하였다. 환자는 성장 장애, 발단 지연, 소두증, 반복되는 감염 및 난치성 뇌전증 증상을 보였으며, 11세 5개월에 원인 미상으로 갑자기 사망하였다. 이에 저자들은 ${\beta}$-UPD 환자의 장기간의 임상경과에 대해 보고하는 바이다.

Keywords

References

  1. Akiyama T, Shibata T, Yoshinaga H, Kuhara T, Nakajima Y, Kato T, et al. A Japanese case of betaureidopropionase deficiency with dysmorphic features. Brain & development 2017;39:58-61. https://doi.org/10.1016/j.braindev.2016.08.001
  2. van Kuilenburg AB, Dobritzsch D, Meijer J, Meinsma R, Benoist JF, Assmann B, et al. Dihydropyrimidinase deficiency: Phenotype, genotype and structural consequences in 17 patients. Biochim Biophys Acta 2010;1802:639-48. https://doi.org/10.1016/j.bbadis.2010.03.013
  3. Nakajima Y, Meijer J, Dobritzsch D, Ito T, Meinsma R, Abeling NG, et al. Clinical, biochemical and molecular analysis of 13 Japanese patients with beta-ureidopropionase deficiency demonstrates high prevalence of the c.977G > A (p.R326Q) mutation [corrected]. J Inherit Metab Dis 2014;37:801-12. https://doi.org/10.1007/s10545-014-9682-y
  4. van Kuilenburg AB, Dobritzsch D, Meijer J, Krumpel M, Selim LA, Rashed MS, et al. ss-ureidopropionase deficiency: phenotype, genotype and protein structural consequences in 16 patients. Biochim Biophys Acta 2012;1822:1096-108. https://doi.org/10.1016/j.bbadis.2012.04.001
  5. Lee JH, van Kuilenburg AB, Abeling NG, Vasta V, Hahn SH. A Korean Case of beta-Ureidopropionase Deficiency Presenting with Intractable Seizure, Global Developmental Delay, and Microcephaly. JIMD Rep 2015;19:117-21.
  6. Huang M, Graves LM. De novo synthesis of pyrimidine nucleotides; emerging interfaces with signal transduction pathways. Cell Mol Life Sci 2003;60:321-36. https://doi.org/10.1007/s000180300027
  7. Connolly GP, Simmonds HA, Duley JA. Pyrimidines and CNS regulation. Trends Pharmacol Sci 1996;17:106-7. https://doi.org/10.1016/0165-6147(96)20001-X
  8. Van Kuilenburg AB, Stroomer AE, Van Lenthe H, Abeling NG, Van Gennip AH. New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid? Biochem J 2004;379:119-24. https://doi.org/10.1042/bj20031463
  9. Shinohara T, Harada M, Ogi K, Maruyama M, Fujii R, Tanaka H, et al. Identification of a G proteincoupled receptor specifically responsive to beta-alanine. The Journal of biological chemistry 2004;279:23559-64. https://doi.org/10.1074/jbc.M314240200
  10. Schmieden V, Kuhse J, Betz H. A novel domain of the inhibitory glycine receptor determining antagonist efficacies: further evidence for partial agonism resulting from self-inhibition. Molecular pharmacology 1999;56:464-72. https://doi.org/10.1124/mol.56.3.464
  11. Shu J, Lv X, Jiang S, Zhang Y, Zhang C, Meng Y, et al. Genetic analysis of the UPB1 gene in two new Chinese families with beta-ureidopropionase deficiency and the carrier frequency of the mutation c.977G>A in Northern China. Childs Nerv Syst 2014;30:2109-14. https://doi.org/10.1007/s00381-014-2541-1
  12. Nilsson L, Tomson T, Farahmand BY, Diwan V, Persson PG. Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 1997;38:1062-8. https://doi.org/10.1111/j.1528-1157.1997.tb01194.x
  13. Ficker DM, So EL, Shen WK, Annegers JF, O'Brien PC, Cascino GD, et al. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology 1998;51:1270-4. https://doi.org/10.1212/WNL.51.5.1270
  14. Tomson T, Walczak T, Sillanpaa M, Sander JW. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia 2005;46 Suppl 11:54-61.
  15. Lamberts RJ, Thijs RD, Laffan A, Langan Y, Sander JW. Sudden unexpected death in epilepsy: people with nocturnal seizures may be at highest risk. Epilepsia 2012;53:253-7. https://doi.org/10.1111/j.1528-1167.2011.03360.x